Hepatoblastoma is one of the most common malignant liver tumors in young children. Recent evidences have suggested that the abnormalities in Wnt signaling pathway, as seen in frequent mutation of the b-catenin gene, may play a role in the genesis of hepatoblastoma. However, the precise mechanism to cause the tumor has been elusive. To identify novel hepatoblastoma-related genes for unveiling the molecular mechanism of the tumorigenesis, a large-scale cloning of cDNAs and differential screening of their expression between hepatoblastomas and the corresponding normal livers were performed. We constructed four full-length-enriched cDNA libraries using an oligo-capping method from the primary tissues which included two hepatoblastomas with high levels of alpha-fetoprotein (AFP), a hepatoblastoma without production of AFP, and a normal liver tissue corresponded to the tumor. Among the 10 431 cDNAs randomly picked up and successfully sequenced, 847 (8.1%) were the genes with unknown function. Of interest, the expression profile among the two subsets of hepatoblastoma and a normal liver was extremely different. A semiquantitative RT-PCR analysis showed that 86 out of 1188 genes tested were differentially expressed between hepatoblastomas and the corresponding normal livers, but that only 11 of those were expressed at high levels in the tumors. Notably, PLK1 oncogene was expressed at very high levels in hepatoblastomas as compared to the normal infant's livers. Quantitative real-time RT-PCR analysis for the PLK1 mRNA levels in 74 primary hepatoblastomas and 29 corresponding nontumorous livers indicated that the patients with hepatoblastoma with high expression of PLK1 represented significantly poorer outcome than those with its low expression (5-year survival rate: 55.9 vs 87.0%, respectively, p ¼ 0.042), suggesting that the level of PLK1 expression is a novel marker to predict Introduction Hepatoblastoma (HBL) is the most common hepatic cancer in children (Exelby et al., 1975; Weinberg and Finegold, 1983) . However, the etiology of HBL has been unclear in contrast to the adult hepatocellular carcinoma (HCC), in which preceding infection of hepatitis virus is often found (Buendia, 1992; Idilman et al., 1998) . Although most HBLs are sporadic, it is sometimes associated with certain hereditary diseases such as Beckwith-Wiedemann syndrome (Albrecht et al., 1994) and familial adenomatous polyposis (Li et al., 1987; Giardiello et al., 1996; Kinzler and Vogelstein, 1996) . In the former, loss of heterozygosity of chromosome 11p15.5 is frequently observed, and the abnormal regulation of the insulin-like growth factor 2 (IGF2) and the H19 genes at this locus may contribute to the disease (Albrecht et al., 1994; Montagna et al., 1994; Li et al., 1995; Rainier et al., 1995; Yun et al., 1998; Fukuzawa et al., 1999) . In the latter, the APC gene, which is one of the key molecules in Wnt signaling, was found to be constitutively mutated (Kinzler and Vogelstein, 1996) .
Increasing evidence suggests that Wnt signaling pathway also plays an important role in the genesis of sporadic hepatoblastomas. A high frequency (more than 60% in some reports) of somatic mutations in the bcatenin gene has recently been reported in sporadic tumors (Koch et al., 1999; Wei et al., 2000; Takayasu et al., 2001; Buendia, 2002) . Mutant b-catenin proteins accumulate in the nucleus, resulting in stimulating transcription of the target genes such as c-myc and cyclin D1 (Morin et al., 1997; Polakis, 1999) . Mutation in the Axin gene, whose product is an antagonist of nuclear accumulation of b-catenin, has also been found in HBL and may contribute to the pathogenesis of the tumors without b-catenin mutation (Taniguchi et al., 2002; Miao et al., 2003) . However, the molecular mechanism underlying the pathogenesis of HBL is still largely unknown.
Recent progress in therapeutic strategies including intensive chemotherapy and liver transplantation improved the outcome of the patients with HBL. However, the prognosis of a significant fraction of the tumors still remains poor. The clinical markers currently used for HBL include staging, which is a major instrument for assessing prognosis (Hata, 1990) , serum alpha-fetoprotein (AFP) (Mann et al., 1978) , mitotic activity (Haas et al., 1989) , DNA ploidy (Hata et al., 1991) , nuclear localization of b-catenin (Park et al., 2001) , p53 mutation (Oda et al., 1995) , and chromosomal alteration (Weber et al., 2000) . Serum AFP level is used as a diagnostic marker to monitor the tumor progression, responsiveness to the therapy, and recurrence after the treatment. Extremely high levels of serum AFP are reported to be associated with aggressiveness of the tumors with unfavorable outcome (van Tornout et al., 1997) , except some reports showing that there is no significant relationship between initial serum AFP levels and prognosis of the patients with HBL (Ortega et al., 1991; von Schweinitz et al., 1994) . Moreover, the tumor with low levels of serum AFP often grows rapidly and is often reluctant to chemotherapy (von Schweinitz et al., 1995) . The other genetic markers including DNA ploidy, chromosomal aberration, and p53 mutation are not so powerful clinical indicators. Even the nuclear localization of b-catenin and/or mutation of the b-catenin gene appear to lose their impact as a prognostic factor when combined with the grade of histological differentiation because of its close correlation with the latter (Takayasu et al., 2001) . Therefore, we may need to find novel markers to predict the patient's outcome in a comprehensive way.
To understand the molecular mechanism of the genesis and progression of HBL, as well as to develop a novel diagnostic and therapeutic system for the tumor, we have randomly cloned 10 431 cDNAs expressed in primary HBL tissues and a normal infant's liver by using full-length-enriched oligo-capping cDNA libraries. In the present study, we have identified 86 genes differentially expressed between HBLs and their corresponding normal livers. One of such genes, PLK1, showed a significantly high expression in the formers as compared with the latters, and its high expression was significantly associated with poor prognosis of HBLs.
Results

Expression profiles of primary HBLs and a normal liver
To obtain the genes expressed in primary HBLs and normal infant's liver, we constructed oligo-capping cDNA libraries from two primary HBLs with increased AFP secretion (HMFT, HYST), a primary HBL without AFP secretion (HKMT), and a corresponding normal liver (HMFN). After cloning 3000 cDNAs from each of the four cDNA libraries, 2289, 2837, 2537, and 2768 clones from the libraries of HMFT, HYST, HKMT, and HMFN, respectively, were successfully end-sequenced. Homology search against the public databases of those 10 431 clones by BLAST program revealed that 847 clones (8.1%) in total contained novel sequences which had not been annotated (Table 1) .
To elucidate the gene expression pattern in each cDNA library, we compared expression profile of the known genes that appeared in three different kinds of libraries, a HBL with positive AFP (HMFT), a HBL with negative AFP (HKMT), and an infant's liver (HMFN) ( Table 2 ). BodyMap (Okubo et al., 1992) and a serial analysis of gene expression (SAGE) (Velculescu et al., 2000) are very good methods to quickly provide quantification of the levels of all mRNAs in certain tissues and cell types by high throughput end-sequencing of cDNA clones. In this study, we applied the former method by counting cDNA clones to show each expression profile of HBL tumors or a non-tumorous tissue. Although each library consists of 3000 clones, which may be a rather small number, the frequency of each cDNA appearance provides a hint to understand each tissue's genetic background.
Overall, the most frequently appeared gene was albumin as expected, which was extremely low in the tumor with negative AFP. Genes involved in cellular structure and/or maintenance, glucose and lipid metabolisms, and a part of protein synthesis and its transport were frequently found in the normal liver library. On the (Hsieh et al., 1999; Wang et al., 2000) , frequently appeared in the HKMT library. In addition, vimentin, RNA-binding motif protein, and RAP1B also frequently appeared in the HKMT library, but hardly in the HMFT library with AFP secretion. Thus, HBL with positive AFP and that with negative AFP seem to have a distinct gene expression profile, resulting in different biological characteristics.
Identification of the differentially expressed genes between HBLs and normal livers
To identify differentially expressed genes between HBLs and their corresponding normal livers, 1188 independent genes which included all of the 847 genes with unknown function and 341 known genes that were related to cellular functions including cell growth and differentiation among the 10 431 cDNAs were selected and subjected to semiquantitative RT-PCR analysis ( Figure 1a ). The complementary DNAs reverse-transcribed from total RNA obtained from eight tumors and their corresponding normal livers were used as PCR templates after normalization with GAPDH expression. As a result, we found that 75 genes were expressed at higher levels in normal livers than in HBLs, whereas only 11 genes were expressed at higher levels in the tumors than in normal livers. Figure 1a shows the representatives of the results of differential screening using semi-quantitative RT-PCR and Table 3 lists 46 differentially expressed genes with known functions. We classified those differentially expressed genes into 12 categories according to their known functions. The genes preferentially expressed in normal liver showed the profiles which reflected normal liver function. Consistent with the previous reports about HBL and hepatocellular carcinoma (von Horn et al., 2001; Xu et al., 2001; Kinoshita and Miyata, 2002) , Insulin-like growth factor binding protein-3 (IGFBP-3), aldolase B, ceruloplasmin, and c-reactive protein were downregulated in HBLs as compared with the normal livers. The expression of IGF2, whose product has mitogenic activity, is upregulated in HBLs, suggesting that the IGF axis may be involved in development of the tumor (Gray et al., 2000) . Four known genes which were expressed at high levels in HBLs (tumor4normal liver) include GTP-binding . The RAN protein is involved in the control of nucleo-cytoplasmic traffic of many nuclear proteins through formation of the transport nuclear pore complex (Ribbeck et al., 1998) . Nagata et al. (2003) also reported that RAN is upregulated in HBLs by oligonucleotide DNA array experiment. The LDL receptor 1 binds LDL, a major plasma cholesterolcarrying lipoprotein, and plays an important role in cholesterol homeostasis (Sudhof et al., 1987; Goldstein and Brown, 1990; Hamanaka et al., 1992) . NPC1 is a causal gene of Niemann-Pick type C disease which is an autosomal recessive lipid storage disorder that affects the viscera and central nervous system (Brady et al., 1989) . It encodes a protein with sequence similarity to the morphogen receptor 'patched', and to the cholesterol-sensing regions of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (Loftus et al., 1997) and is involved in the intracellular trafficking of cholesterol. Concerning the differentially expressed genes which contained unknown sequences, those cDNA sequences have been submitted to the public database (Genbank/DDBJ Accession numbers: AB07 3346-AB073347, AB073382-AB073387, AB073599-AB0 73614, and AB075869-AB075881). Interestingly, only one known gene, lymphocyte alpha-kinase (LAK), showed distinct expression pattern between HBLs with mutant b-catenin and those with wild type b-catenin ( Figure 1a) . We next examined expression pattern of the novel genes in human multiple tissues by semi-quantitative RT-PCR and found that at least five genes were specifically expressed in the liver (a part of the data is shown in Figure 1b) . Since the oncogene PLK1 (pololike kinase-1) was expressed in HBLs at significantly high levels as compared with the corresponding normal livers, we further examined the role of its expression in HBL.
PLK1 oncogene is overexpressed in HBLs
Recent studies have demonstrated that the preferential expression of PLK1 mRNA is associated with some cancers including non-small-cell lung cancer (Wolf et al., 1997) , squamous cell carcinoma of the head and neck (Knecht et al., 1999) , and esophageal carcinoma (Tokumitsu et al., 1999) . However, the role of PLK1 in HBL has never been reported. As indicated by semiquantitative RT-PCR described above, we found that PLK1 mRNA expression in HBLs is higher than in normal livers (Figure 2a) . Northern blot analysis also confirmed its higher expression in HBLs (Figure 2b) . We also performed Southern blot analysis by using the genomic DNAs obtained from primary HBLs and human placenta as a control, and probed with the PLK1-specific DNA fragment. However, we failed to find any clue of rearrangements or amplification of the PLK1 gene locus (data not shown).
To examine the clinical significance of the expression level of PLK1, we performed quantitative real-time RT-PCR analysis using 74 primary hepatoblastomas and 29 corresponding normal liver samples (Figure 3a) . The average arbitrary values of PLK1 expression in HBLs and normal livers were 28.976.7 and 4.170.76, respectively (mean7s.e.m., Po0.01). The average values in alive and dead cases were 21.775.2 (n ¼ 61) and 62.4728.2 (n ¼ 13), respectively (p ¼ 0.021). When we compared the expression levels of PLK1 between 24-paired HBLs and their corresponding normal livers, the former in HBL samples was significantly higher in comparison with the latter (Po0.01) (Figure 3b ). We also examined the relationship between the expression levels of PLK1 and clinicopathological data of HBLs. Statistically significant correlation was observed only between histology and PLK1 expression (p ¼ 0.041). The expression level of PLK1 in the tumors with poorly differentiated histology was higher than those with the well-differentiated one. The other clinicopathological factors such as age, clinical stage, and b-catenin mutation did not show a statistical significance with PLK1 expression.
To further examine whether the PLK1 expression was associated with the outcome of the patients with HBL, we performed a Kaplan-Meier analysis (Figure 4) . The distinction between high and low levels of PLK1 expression was based on the median value (low, PLK1o13 d.u.; high, PLK1Z13 d.u.). Since the overall survivals of 15 out of 74 cases were unknown, 59 cases were applied to the analysis. The 5-year survival rates of the groups with high and low PLK1 expression were 55.9 and 87.0%, respectively (P ¼ 0.042). The univariate analysis showed that both PLK1 expression (P ¼ 0.015) and histology (P ¼ 0.025) have a significant prognostic importance (Table 4) . The multivariate analysis demonstrated that PLK1 expression was significantly related to survival, after controlling b-catenin mutation, age, stage, (Table 5) .
Discussion
HBL is one of the embryonal tumors in close relation to the normal as well as abnormal tissue development. To understand the molecular basis of the genesis of HBL, here we randomly cloned a large number of genes expressed in HBLs with or without AFP production and in a non-tumorous infant's liver. Extensive screening for the differentially expressed genes between the tumors and their corresponding normal livers has successfully identified at least 86 genes including 40 with unknown function, which may potentially contribute to develop new therapeutic strategies against HBLs with poor prognosis.
HBL cDNA libraries
We have identified the genes with unknown function in approximately 8% of the total 10 431 clones obtained from our oligo-capping cDNA libraries. The comparison of the frequently appeared genes in each libraries shows that expression profile is relatively similar between AFP-positive HBL and the normal part of the infant's liver, whereas it is very different between AFPpositive and AFP-negative tumors, in which many genes (Table 2 ). In the library of the latter tumor, vimentin, RNA-binding motif protein, Wnt inhibitory factor-1, dickkopf, and RAP1B are frequently appeared, whereas they are hardly appeared in the other libraries. Wissmann et al. (2003) have recently reported that WIF1 is downregulated in various cancers (prostate cancer, breast cancer, non-small-cell lung cancer, and bladder cancer), and suggested that loss of WIF1 expression may be an early event in tumorigenesis in those tissues. It is notable that, in contrast to AFPpositive HBLs, the patient's outcome of the tumor with negative AFP is very poor, though the incidence of the latter tumor is low (von Schweinitz et al., 1995) . This suggests that AFP-positive and AFP-negative HBLs have a different genetic as well as biological background. In addition, recent reports have demonstrated that frequent mutation of the b-catenin gene and nuclear accumulation of its protein product are one of the main causes of the tumorigenesis of HBL. The APC and Axin genes are also mutated in some HBLs (Oda et al., 1996; Miao et al., 2003; Thomas et al., 2003) , indicating that Wnt signaling pathway plays an important role in causing the tumors, most of which are AFP-positive. Therefore, the poor-prognostic HBL without producing AFP might be caused by the particular mechanism additional to or other than the abnormality of Wnt signaling pathway. Although the appearance frequency of the genes in each library does not always reflect the actual expression levels of each gene, it may at least in part show the differences among the tumor subsets with different genetic abnormalities. As our libraries contain many genes involved in liver development, normal liver functions, and carcinogenesis, they must be useful for making a liver-proper cDNA microarray to analyse expression profiles of HBL, viral infection-induced hepatitis, liver cirrhosis, and HCC.
Differentially expressed genes between HBLs and the corresponding normal livers cDNA microarray, which is often applied to a comprehensive gene expression analysis, is able to detect many genes that are differentially expressed between tumors and normal tissues (Okabe et al., 2001; Nagata et al., 2003) . However, it is expensive and needs further confirmation of the selected genes by a semi-quantitative RT-PCR or a real-time RT-PCR method. Therefore, using semi-quantitative RT-PCR and the specific primers of 1188 cDNAs, we have identified 86 genes differentially expressed between HBLs and their corresponding normal livers. Surprisingly, 75 out of 86 genes are preferentially expressed in the latter tissues, and only 11 including RAN, PLK1, NPC1, and OLR1 known genes are expressed at high levels in HBLs. One of the reasons of this result may be that many gene products, which are necessary for full function in the matured liver metabolism, are dispensable for the malignant growth of the tumor except for the very limited genes. The results of some differentially expressed genes are consistent with those in the previous reports. von Horn et al. (2001) have shown that the mRNA levels of insulin-like growth factor-binding proteins including IGFBP-3 are decreased in HBLs than in normal livers. Kinoshita and Miyata (2002) have also reported that aldolase B mRNA is downregulated in over 50% of 20 HCCs examined. They proposed that the measurement of aldolase activity in serum is useful to determine the number of collapsed hepatic cells in cirrhosis. Recently, evidences suggest that not only mutant b-catenin but also wild-type bcatenin localize in the cellular nuclei of HBL as well as some other cancers (Rimm et al., 1999; Takayasu et al., 2001) . The increased expression of the Ran gene in HBLs might be correlated with the shuttling of bcatenin and/or other related proteins between cytoplasm and nucleus in the tumor cells.
Owing to constitutive activation of Wnt signaling in most of the HBLs, the 86 genes differentially expressed between the tumor and its corresponding normal liver were expected to contain downstream target genes of Wnt signaling pathway that might regulate early stage of the hepatic development. In this study, however, only the lymphocyte alpha-kinase (LAK) gene was found to be differentially expressed at high levels in HBLs with wildtype b-catenin and at low levels in those with b-catenin mutation. LAK is a new class of protein kinases with a novel catalytic domain, but its precise function is currently unknown (Ryazanov et al., 1999) . Thus, our result may suggest that the target genes of the Wnt signaling pathway are commonly affected in HBLs, regardless of the presence or absence of b-catenin mutation.
PLK1 as a prognostic indicator of HBL
PLK1 (polo-like kinase 1), the human counterpart of polo in Drosophila melanogaster and of CDC5 in Saccharomyces cerevisiae, encodes a serine/threonine kinase with polo-box domains (Clay et al., 1993) . PLK1 is crucial for various events of mitotic progression including centrosome maturation (Lane and Nigg, (Glover et al., 1996) , activation of cyclin B/Cdc2 (Qian et al., 1998; ToyoshimaMorimoto et al., 2001) , and regulation of anaphasepromoting complex (Kotani et al., 1998; Nigg, 1998) . Elevated expression of PLK1 is also found in different types of adult cancers including non-small-cell lung cancer, head and neck tumors, esophageal carcinomas, melanomas, and colorectal cancers (Wolf et al., 1997; Knecht et al., 1999; Tokumitsu et al., 1999; Dietzmann et al., 2001; Takai et al., 2001) , implying its critical role in tumorigenesis. In the present study, we have found that PLK1 is upregulated in primary HBLs, and that its mRNA expression levels are significantly correlated with poor outcome of the patients. Multivariate Cox regression analysis indicated that PLK1 expression could be an independent prognostic factor from b-catenin mutation, age, stage, or histology. However, clinical stage did not show a significant correlation with PLK1 expression, though it is one of the critical prognostic markers. One of the possible reasons may be that the 59 tumors we used for statistical analysis include two unusual patients, one had stage 4 tumor with good prognosis and another case had stage 1 tumor with poor prognosis. These might have reduced the significance of the tumor stage in patients' survival in our sample set. It is notable that, among the 1188 genes we have screened for differential expression, PLK1 is the only one known oncogene overexpressed in the HBL tissues. Smith et al. (1997) have reported that constitutive expression of PLK1 in NIH3T3 cells causes oncogenic focus formation and forms tumors in nude mice. Furthermore, Liu and Erikson (2003) have recently shown that the application of small interfering RNA which specifically depletes PLK1 expression in cancer cells inhibits cell proliferation, arrests cell cycle, and induces apoptosis. Thus, PLK1 may play a crucial role in causing HBL and other cancers. It may be interesting to examine whether PLK1 is a target of b-catenin transported from the cytosol into the nucleus. The disruption of PLK1 function could be a future therapeutic tool for the aggressive type of hepatoblastomas.
In conclusion, our HBL cDNA project has provided a large number of genes related to liver development, metabolism, and carcinogenesis. We are currently applying these genes to the cDNA microarray system. Our cDNA resource should be an important tool to understand the molecular mechanism of the genesis of HBL as well as to develop new diagnostic and therapeutic strategies against the aggressive tumors in the future.
Materials and methods
Clinical materials
Tumor tissues and their corresponding normal liver tissues were frozen at the time of surgery and stored at À801C until use. All specimens were provided from the Tissue Bank of the Japanese Study Group for Pediatric Liver Tumor (JPLT) (Uotani et al., 1998) . A total of 74 HBL samples (seven were classified as being stage 1, 17 as stage 2, 26 as stage 3, 15 as stage 4, and nine were unknown stages) were used in this study. The tumors were staged according to the Japanese histopathological classification of HBL (Hata, 1990) . From 1991 to 1999, HBLs had been treated by combination chemotherapy using cisplatin and THP-adriamycin according to the JPLT-1 protocol (Sasaki et al., 2002) . After 2000, a more intensive chemotherapeutic regimen, ITEC (ifosfamide, THP-adriamycin, etoposide, and carboplatin), has been utilized for tumors that prove resistant to the combination chemotherapy in the JPLT-2 study. Among the 74 tumor samples we examined, 36 and 35 tumor tissues were obtained prior to and after chemotherapy, respectively, and the remaining three were unknown. In the same sample set, 59 tumors were accompanied by outcome information and used for making survival curves, among which 31 and 28 tissues were obtained prior to and after chemotherapy, respectively. Tumor histology was also classified according to Hata (1990) . 'Poor histology' indicates 'poorly differentiated (embryonal type)', and 'well histology' indicates 'well-differentiated (fetal type)'. The informed consents were obtained in each institution or hospital. High molecular weight DNA and total RNA of these samples were prepared as described previously (Ichimiya et al., 1999) .
Construction of oligo-capping cDNA libraries
Four oligo-capping cDNA libraries, two (HMFT, HYST) derived from HBLs with secretion of AFP, one (HKMT) from HBL without AFP secretion, and one (HMFN) from the corresponding normal liver, were constructed according to the method previously described (Suzuki et al., 1997) . These were approved by the institutional review board. The oligo-capping method enables full-length cDNA cloning with high efficiency. The 12 000 cDNA clones in total were randomly picked up and single-run sequencing was performed. Nucleotide sequence of both ends for each cDNA clone was homology-searched against the public nucleotide database using the BLAST program at the National Center for Biotechnology Information (NCBI) (Genbank release 122, January 2001).
Differential screening of the genes by semi-quantitative RT-PCR
The eight samples were selected as PCR templates to screen for the differentially expressed genes. Cases 58 and 81 were defined as stage 2 HBL, cases 10, 67, 78, and 85 were in stage 3, case 14 was in stage 4. Among those eight tumors, four (cases 14, 67, 78, and 81) had the mutant b-catenin, and the others (cases 10, 58, 77, and 85) not. Mutation analysis for b-catenin was performed as described previously (Takayasu et al., 2001) . The differential expression of the genes between the HBL and normal livers was confirmed at least twice using semiquantitative RT-PCR. The individual gene-specific PCR primer sequences were determined by using Primer3 program (provided at Washington University). For cDNA templates, 5 mg of total RNA was converted to cDNA using random primers (Takara, Otsu, Japan) with SuperScript II RNaseH -reverse transcriptase (Gibco BRL, Rockville, MD, USA). Those cDNAs were at first amplified with GAPDH primers for 27 cycles and the amounts of the PCR products were measured by ALF Expresst sequencer and normalized. The amplification was performed 35 or 40 cycles of 951C for 30 s, 57 or 59 or 611C for 15 s and 721C for 60 s, and the final extension was at 721C for 5 min, using a Perkin-Elmer Thermalcycler 9700 (Perkin-Elmer, Foster City, CA, USA). The PCR products were run on 2% agarose gels and stained with ethidium bromide. We defined the gene as differentially expressed when it exhibits differential expression between the tumor and its corresponding normal liver in more than four out of the eight samples.
Northern blot analysis
In all, 25 mg of total RNA from the primary HBLs, HCC, and their corresponding normal livers were subjected to Northern analysis. Total RNA was prepared according to the method of Chomczynski and Sacchi (1987) . Total RNA was fractionated by electrophoresis on 1% agarose gel containing formaldehyde, transferred onto a nylon membrane filter, and immobilized by UV crosslinking. The hybridization cDNA probe was a 976-base pair human PLK1 cDNA fragment and labeled with [a-32 P]-dCTP using the BcaBEST random priming kit (Takara Biomedicals). The filter was hybridized at 651C in a solution containing 1 M NaCl, 1% SDS, 7.5% dextran sulfate, 100 mg/ml of heat-denatured salmon sperm DNA, and radiolabeled probe DNA.
Quantitative real-time RT-PCR of PLK1
The primer set for amplification of the PLK1 and probe sequence are as follows: forward primer, 5 0 -GCTGCACAAG AGGAGGAAA-3 0 ; reverse primer, 5 0 -AGCTTGAGGTCTC-GATGAATAAC-3 0 ; probe, 5 0 -CCTGACTGAGCCTGAGG CCCGATAC-TA-3 0 . Taqman GAPDH control reagents (Perkin-Elmer/Applied Biosystems) were used for the amplification of GAPDH as recommended by the manufacturer. PCR was performed using ABI Prism 7700 Sequence Detection System (Perkin-Elmer/Applied Biosystems). In all, 2 ml of cDNA was amplified in a final volume of 25 ml containing 1 Â Taqman PCR reaction buffer, 200 mM each dNTP, 0.9 mM each primer, and 200 nM Taqman probe. The optional thermal cycling condition was as follows: 40 cycles of a two-step PCR (951C for 15 s, 601C for 60 s) after the initial denaturation (951C for 10 min). Experiments were carried out in triplicate for each data point.
Statistical analysis
Statistical analyses were performed using Mann-Whitney's Utest and Cox regression. A P-value of less than 0.05 was considered significant.
